Spain’s Medicines Agency Sets Technical Requirements for Veterinary Drug Registration
The Spanish Agency for Medicines and Health Products (AEMPS) has published a resolution establishing the technical requirements for the registration of non-biological veterinary medicinal products. The resolution, signed by the agency’s director María Jesús Lamas Díaz, outlines the scientific and administrative criteria that applicants must meet when seeking authorization for veterinary medicines in Spain. This development reflects ongoing efforts to harmonize regulatory standards within the European Union whereas ensuring the safety, efficacy, and quality of veterinary medicinal products available on the market.
The resolution applies specifically to non-biological veterinary medicinal products, which include chemically synthesized active substances such as antibiotics, antiparasitics, and anti-inflammatory agents used in the treatment and prevention of diseases in livestock and companion animals. Biological products, such as vaccines derived from living organisms, are subject to separate regulatory frameworks and are not covered by this particular guidance.
According to the AEMPS, the technical requirements are aligned with the provisions of Directive 2001/82/EC of the European Parliament and of the Council on the veterinary medicinal products, as amended, and subsequent EU regulations governing the authorization and monitoring of veterinary medicines. The agency emphasizes that compliance with these requirements is essential for obtaining a marketing authorization that is valid across member states through the centralized, mutual recognition, or decentralized procedures established under EU law.
Applicants must submit a comprehensive dossier containing detailed information on the quality, safety, and efficacy of the veterinary medicinal product. The quality section requires data on the manufacturing process, specifications of the active substance and excipients, stability studies, and batch analysis results. Safety assessments must include pharmacotoxicity studies, target animal safety, user safety, and environmental risk evaluations. Efficacy data should demonstrate that the product achieves the claimed therapeutic or preventive effect under the conditions of use specified in the summary of product characteristics.
The resolution also clarifies the format and structure of the application dossier, which must follow the Common Technical Document (CTD) format agreed upon by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and adapted for veterinary use. This standardized format facilitates regulatory review and promotes consistency across international submissions.
In addition to the technical specifications, the AEMPS resolution outlines procedural aspects of the registration process, including timelines for assessment, requirements for post-authorization monitoring, and obligations for pharmacovigilance. Marketing authorization holders are required to report adverse reactions, lack of efficacy, and any emerging safety concerns through the national pharmacovigilance system, which feeds into the EU-wide EudraVigilance veterinary database.
The agency states that the publication of these requirements aims to increase transparency for pharmaceutical companies, veterinary practitioners, and other stakeholders involved in the development and distribution of veterinary medicines. By clearly defining expectations, the AEMPS seeks to streamline the evaluation process while maintaining high standards for public and animal health protection.
María Jesús Lamas Díaz, who has served as director of the AEMPS since 2018, has overseen several initiatives to strengthen the agency’s role in both human and veterinary medicines regulation. Her leadership has been marked by efforts to enhance collaboration with European regulatory networks, promote innovation in medicinal product development, and ensure preparedness for public health challenges, as noted in her public statements and institutional communications.
The resolution is available on the official AEMPS website in the section dedicated to regulatory publications and veterinary medicines. Stakeholders are encouraged to consult the full document for detailed technical specifications and to contact the agency’s veterinary medicines department for guidance on specific submission requirements.
As the European Union continues to refine its regulatory framework for veterinary medicines, including ongoing discussions about the revision of the basic legal framework, national agencies like the AEMPS play a key role in implementing and interpreting these rules at the national level. The publication of technical requirements represents a routine but significant step in ensuring that veterinary medicinal products meet the necessary standards before they reach animals and, by extension, the food chain and environment.
For the most current information on veterinary medicinal product registrations in Spain, including updates to guidelines, public consultations, and decisions on individual applications, interested parties should refer to the AEMPS veterinary medicines portal or subscribe to the agency’s official notifications.
We invite our readers to share their perspectives on regulatory developments in veterinary medicine and how they impact animal health, agricultural practices, and public safety. Join the conversation by commenting below or sharing this article with colleagues in the veterinary, pharmaceutical, and agricultural sectors.